The European and American guidelines on dyslipidemia management overlap but also diverge in critical ways. A Johns Hopkins cardiologist highlights similarities and differences.
Recent Recreational Drug Use Ups Risk of Repeat Serious CV Event: Daily Dose
Your daily dose of the clinical news you may have missed.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Finerenone Improves Outcomes in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction
ESC 2024: Findings from the FINEARTS-HF clinical trial provide the first definite evidence that an MRA can be beneficial in patients with HFmrEF/HFpEF.
Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?
Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.
Plant-Based Fats Reduce Risk for Overall, CVD Death: Daily Dose
Combination Statin Plus Ezetimibe More Effective than High-Dose Statin to Reduce LDL-C in People with ASCVD
In secondary CVD prevention, low/moderate-dose statins plus ezetimibe were superior to high-dose statin for reducing biomarkers, myalgias but did not reduce MACE.